Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients

Rheumatology International, 05/08/2012

Despite the higher initial fracture risk in the alfacalcidol group, 2–year treatment with this active D–hormone prodrug showed a higher therapeutic efficacy in terms of bone mineral density (BMD), falls and fractures. One important advantage of alfacalcidol may be that it is effective even in patients with mild–to–moderate renal insufficiency.

Print Article Summary Cat 2 CME Report